Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Pinato

Showing results (91-100 of 238) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2024
Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of DeathGiuseppe Cabibbo, Ciro Celsa, Salvatore Battaglia, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2019
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinomaJessica Howell, Stephen R Atkinson, David J Pinato, et al.
Journal for Immunotherapy of Cancer|January 13, 2021
Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expressionMarina Natoli, John Gallon, Haonan Lu, et al.
Hepatology Communications|September 14, 2023
Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapyBernhard Scheiner, Katharina Lampichler, Katharina Pomej, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 1, 2019
Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor TherapyDavid J Pinato, Heather Urus, Thomas Newsom-Davis, et al.
Plos One|January 4, 2013
A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteersVincenzo Libri, Andrew P Brown, Giulio Gambarota, et al.
European Journal of Cancer (Oxford, England : 1990)|July 3, 2022
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockadeKazuki Takada, Sebastiano Buti, Melissa Bersanelli, et al.
British Journal of Cancer|July 22, 2025
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patientsKenneth Sooi, Tuan Zea Tan, Jae-Weon Kim, et al.
Liver Cancer|July 9, 2021
Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-AnalysisArndt Vogel, Lorenza Rimassa, Hui-Chan Sun, et al.
BMC Cancer|March 24, 2021
PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinomaDavid J Pinato, Alessio Cortellini, Ajithkumar Sukumaran, et al.
Pageof 24

Showing results (91-100 of 238) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2024
Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of DeathGiuseppe Cabibbo, Ciro Celsa, Salvatore Battaglia, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2019
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinomaJessica Howell, Stephen R Atkinson, David J Pinato, et al.
Journal for Immunotherapy of Cancer|January 13, 2021
Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expressionMarina Natoli, John Gallon, Haonan Lu, et al.
Hepatology Communications|September 14, 2023
Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapyBernhard Scheiner, Katharina Lampichler, Katharina Pomej, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 1, 2019
Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor TherapyDavid J Pinato, Heather Urus, Thomas Newsom-Davis, et al.
Plos One|January 4, 2013
A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteersVincenzo Libri, Andrew P Brown, Giulio Gambarota, et al.
European Journal of Cancer (Oxford, England : 1990)|July 3, 2022
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockadeKazuki Takada, Sebastiano Buti, Melissa Bersanelli, et al.
British Journal of Cancer|July 22, 2025
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patientsKenneth Sooi, Tuan Zea Tan, Jae-Weon Kim, et al.
Liver Cancer|July 9, 2021
Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-AnalysisArndt Vogel, Lorenza Rimassa, Hui-Chan Sun, et al.
BMC Cancer|March 24, 2021
PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinomaDavid J Pinato, Alessio Cortellini, Ajithkumar Sukumaran, et al.
Pageof 24